The role of personalized medicine in the intensive care unit
https://doi.org/ 10.24411/2588-0527-2018-10007
Abstract
This article highlights modern approaches in the diagnosis and treatment of critical patients in terms of personalized medicine. Biomarkers of such conditions as acute renaL failure, acute respiratory distress syndrome, sepsis are described. The roLe of pharmacokinetics and pharmacogenomics in the intensive care unit is reported.
About the Authors
K. S. Ivanova
Federal State Autonomous Educational Institution of Higher Education L.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of the Russian Federation (Sechenovskiy University)
Russian Federation
Russian Federation
A. E. Tsygankova
Federal State Autonomous Educational Institution of Higher Education L.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of the Russian Federation (Sechenovskiy University)
Russian Federation
Russian Federation
Y. A. Kovalenko
Federal State Autonomous Educational Institution of Higher Education L.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of the Russian Federation (Sechenovskiy University)
Russian Federation
Russian Federation
M. S. Zabolotnaya
Federal State Budgetary Educational Institution of Higher Education «Omsk State Medical University» of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
References
1. Chan IS, Ginsburg GS. Personalized medicine: progress and promise. Annu Rev Genomics Hum Qenet. 2011;12:217-244. DOI: 10.1146/annurev-genom-082410-101446
2. Jain KK. From molecular diagnostics to personalized medicine. Expert Rev Mol Diagn. 2002 Jul;2(4):299-301. DOI: 10.1586/14737159.2.4.299
3. Freeman BD, McLeod HL. Challenges of implementing pharmacogenetics in the critical care environment. Nat Rev Drug Discov. 2004 Jan;3(1):88-93. DOI: 10.1038/nrd1285
4. Allen JM, Gelot S. Pharmacogenomics in the intensive care unit: focus on potential implications for clinical practice. Recent Pat Biotechnol. 2014;8(2):116-122.
5. Hulot JS, Bura A., Villard E., et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006; 108: 2244-2247. 2006 Oct 1;108(7):2244- 2247. DOI: 10.1182/blood-2006-04-013052
6. Umemura K., Furuta T., Kondo K. The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects. J. Thromb Haemost. 2008 Aug;6(8):1439-1441. DOI: 10.1111/j.1538-7836.2008.03050.x
7. Brandt JT, Close SL, Iturria SJ, et al. Common poly- morphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J. Thromb Haemost. 2007 Dec;5(12):2429-2436. DOI: 10.1111/j.1538-7836.2007.02775.x
8. Simon T., Bhatt DL, Bergougnan L., et al. Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects. Clin Pharmacol Ther. 2011 Aug;90(2):287-295. DOI: 10.1038/clpt.2011.127
9. Bodin L., Verstuyft C., Tregouet DA, et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K. epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood. 2005 Jul 1 ; 106(1): 135-140. DOI: 10.1182/blood-2005-01-0341
10. McGuire MC, Nogueira CP, Bartels CF, et al. Identi cation of the structural mutation responsible for the dibucaine-resistant (atypical) variant form of human serum cholinesterase. Proc Natl Acad Sci USA. 1989;86(3): 953-957.
11. Kimmel SE, French B., Kasner SE, et al. COAG Investigators. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N. Engl J. Med. 2013 Dec 12;369(24):2283-2293. DOI: 10.1056/NEJMoa1310669
12. Pirmohamed M., Burnside G., Eriksson N., et al. EU-PACT Group. A randomized trial of genotype-guided dosing of warfarin. N. Engl J. Med. 2013 Dec 12;369(24):2294-2303. DOI: 10.1056/NEJMoa1311386
13. Sanderson S., Emery J., Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Qenet Med. 2005 Feb;7(2):97-104. DOI: 10.109701.GIM.0000153664.65759.CF
14. Kohli U., Muszkat M., Sofowora GG, et al. Effects of variation in the human alpha2A- and alpha2C-adrenoceptor genes on cognitive tasks and pain perception. Eur J. Pain. 2010 Feb;14(2):154-159. DOI: 10.1016/j.ejpain.2009.04.003
15. Kurnik D., Muszkat M., Sofowora GG, et al. Ethnic and genetic determinants of cardiovascular response to the selective alpha 2-adrenoceptor agonist dexmedetomidine. Hypertension. 2008 Feb;51(2):406-411. DOI: 10.1161/HYPERTENSIONAHA.107.098939
16. Prabhakaran P., Ware LB, White KE, et al. Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury. Am J. Physiol Lung Cell Mol Physiol. 2003 Jul;285(1):L20-28. DOI: 10.1152/ajplung.00312.2002
17. Gentile LF, Cuenca AG, Vanzant EL, et al. Is there value in plasma cytokine measurements in patients with severe trauma and sepsis? Methods. 2013 May 15;61(1):3-9. DOI: 10.1016/j.ymeth.2013.04.024
18. Rhodes A., Evans LE, Alhazzani W., et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017 Mar;43(3):304-377. DOI: 10.1007/s00134-017-4683-6
19. Ferrer R., Martin-Loeches I., Phillips G., et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med. 2014 Aug;42(8):1749-1755. DOI: 10.1097/CCM.0000000000000330
20. Zadroga R., Williams DN, Gottschall R., et al. Comparison of 2 blood culture media shows significant differences in bacterial recovery for patients on antimicrobial therapy. Clin Infect Dis. 2013 Mar;56(6):790-797. DOI: 10.1093/cid/cis1021
21. Reinhart K., Bauer M., Riedemann NC, et al. New approaches to sepsis: molecular diagnostics and biomarkers. Clin Microbiol Rev. 2012 Oct;25(4):609-634. DOI: 10.1128/CMR.00016-12
22. Vincent JL, Teixeira L. Sepsis biomarkers. Value and limitations. Am J. Respir Crit Care Med. 2014 Nov 15;190(10):1081 - 1082. DOI: 10.1164/rccm.201410-1895ED
23. Pierrakos C., Vincent JL. Sepsis biomarkers: a review. Crit Care. 2010;14(1):R15. DOI: 10.1186/cc8872
24. Uzzan B., Cohen R., Nicolas P., et al. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med. 2006 Jul;34(7):1996-2003. DOI: 10.1097/01.CCM.0000226413.54364.36
25. Pizzolato E., Ulla M., Galluzzo C., et al. Role of presepsin for the evaluation of sepsis in the emergency department. Clin Chem Lab Med. 2014 Oct;52(10):1395-1400. DOI: 10.1515/cclm-2014-0199
26. Ackland GL, Prowle JR. Presepsin: solving a soluble (CD14) problem in sepsis? Intensive Care Med. 2015 Feb;41(2):351-353. DOI: 10.1007/s00134-014-3642-8
27. Masson S., Caironi P., Spanuth E., et al. ALBIOS Study Investigators. Presepsin (soluble CD14 subtype) and procalcitonin levels for mortality prediction in sepsis: data from the Albumin Italian Outcome Sepsis trial. Crit Care. 2014 Jan 7;18(1):R6. DOI: 10.1186/cc13183
28. Takahashi G., Shibata S., Ishikura H., et al. Presepsin in the prognosis of infectious diseases and diagnosis of infectious disseminated intravascular coagulation: a prospective, multicentre, observational study. Eur J. Anaesthesiol. 2015 Mar;32(3):199-206. DOI: 10.1097/EJA.0000000000000178
29. Behnes M., Bertsch T., Lepiorz D., et al. Diagnostic and prognostic utility of soluble CD 14 subtype (presepsin) for severe sepsis and septic shock during the rst week of intensive care treatment. Crit Care. 2014;18(5):507. DOI: 10.1186/s13054-014-0507-z
30. Masson S., Caironi P., Fanizza C., et al. Circulating presepsin (soluble CD14 subtype) as a marker of host response in patients with severe sepsis or septic shock: data from the multicenter, randomized ALBIOS trial. Intensive Care Med. 2015 Jan;41(1):12-20. DOI: 10.1007/s00134-014-3514-2
31. Reinhart K., Bauer M., Riedemann NC, et al. New approaches to sepsis: molecular diagnostics and biomarkers. Clin Microbiol Rev. 2012 Oct;25(4):609-634. DOI: 10.1128/CMR.00016-12
32. Koyner JL, Parikh CR Clinical utility of biomarkers of AKI in cardiac surgery and critical illness. Clin J. Am Soc Nephrol. 2013 Jun;8(6):1034-1042. DOI: 10.2215/CJN.05150512
33. Gibot S., Béné MC, Noel R., et al. Combination biomarkers to diagnose sepsis in the critically ill patient. Am J. Respir Crit Care Med. 2012 Jul 1; 186(1):65-71. DOI: 10.1164/rccm.201201-0037OC
Review
For citations:
Ivanova K.S., Tsygankova A.E., Kovalenko Y.A., Zabolotnaya M.S. The role of personalized medicine in the intensive care unit. Pharmacogenetics and Pharmacogenomics. 2018;(1):38-42. (In Russ.) https://doi.org/ 10.24411/2588-0527-2018-10007
Views:
433
Email this article 
Post a Comment 